Conservative treatment to slow deterioration of renal function: Evidence-based recommendations

被引:13
作者
Burgess, E [1 ]
机构
[1] Univ Calgary, Dept Med, Calgary, AB, Canada
关键词
progressive renal disease; glomerulonephritis; blood pressure; renoprotection; protein diets; malnutrition;
D O I
10.1046/j.1523-1755.1999.07003.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Despite current specific therapy, progressive deterioration of renal function in patients with primary glomerulonephritis occurs. Nonspecific renoprotective interventions that have been studied include blood pressure control, antihypertensive medications, and protein-restricted diets. To prepare this article, a MEDLINE search was conducted, followed by secondary and tertiary searches. Research papers were assessed for level of evidence, and graded recommendations were formulated. Protein-restricted diets (to 0.4 to 0.6 g/kg/day) are not recommended for all patients with reduced renal function (grade A). Very low-protein diets of 0.4 g/kg/day should be considered for patients with severe renal dysfunction (serum creatinine of more than 350 mu mol/liter; grade A). However, there are concerns about recommending these diets for all patients because of the potential for long-term negative outcomes such as nutritional deficiencies. Target blood pressure for persons with proteinuria of more than 1 g/day should be less than 125/75 mm Hg [mean arterial pressure (MAP) < 92 mm Hg; grade C]. For persons with proteinuria of less than 1 g/day, the target blood pressure should be approximately MAP 98 mm Hg (less than 130/80; grade C). Angiotensin-converting enzyme inhibitor (ACEI) therapy is recommended in preference to placebo, conventional, or P-blocker therapy for renoprotection (grade A). ACEI therapy cannot be recommended above calcium channel blockers in patients with nondiabetic renal disease (grade A).
引用
收藏
页码:S17 / S25
页数:9
相关论文
共 44 条
[1]  
Barsotti G., 1983, Kidney International, V24, pS278
[2]   RENAL PROTECTIVE EFFECT OF STRICT BLOOD-PRESSURE CONTROL WITH ENALAPRIL THERAPY [J].
BAUER, JH ;
REAMS, GP ;
LAL, SM .
ARCHIVES OF INTERNAL MEDICINE, 1987, 147 (08) :1397-1400
[3]  
BERGSTROM J, 1986, CLIN NEPHROL, V25, P1
[4]   LONG-TERM EFFECTS OF ENALAPRIL AND NICARDIPINE ON URINARY ALBUMIN EXCRETION IN PATIENTS WITH CHRONIC RENAL-INSUFFICIENCY - A 1-YEAR FOLLOW-UP [J].
BIANCHI, S ;
BIGAZZI, R ;
BALDARI, G ;
CAMPESE, VM .
AMERICAN JOURNAL OF NEPHROLOGY, 1991, 11 (02) :131-137
[5]   PROGRESSIVE RENAL-DISEASE - ROLE OF RACE AND ANTIHYPERTENSIVE MEDICATIONS [J].
BRAZY, PC ;
FITZWILLIAM, JF .
KIDNEY INTERNATIONAL, 1990, 37 (04) :1113-1119
[6]   PROGRESSION OF RENAL-INSUFFICIENCY - ROLE OF BLOOD-PRESSURE [J].
BRAZY, PC ;
STEAD, WW ;
FITZWILLIAM, JF .
KIDNEY INTERNATIONAL, 1989, 35 (02) :670-674
[7]  
CARRUTHERS SG, 1993, CAN MED ASSOC J, V149, P289
[8]   LONG-TERM BENEFITS OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR THERAPY IN PATIENTS WITH SEVERE IMMUNOGLOBULIN A NEPHROPATHY - A COMPARISON TO PATIENTS RECEIVING TREATMENT WITH OTHER ANTIHYPERTENSIVE AGENTS AND TO PATIENTS RECEIVING NO THERAPY [J].
CATTRAN, DC ;
GREENWOOD, C ;
RITCHIE, S .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 23 (02) :247-254
[9]   LOVASTATIN IN GLOMERULONEPHRITIS PATIENTS WITH HYPERLIPEMIA AND HEAVY PROTEINURIA [J].
CHAN, PCK ;
ROBINSON, JD ;
YEUNG, WC ;
CHENG, IKP ;
YEUNG, HWD ;
TSANG, MTS .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1992, 7 (02) :93-99
[10]   SELECTIVE EFFECT OF LOW PROTEIN DIETS IN CHRONIC RENAL DISEASES [J].
ELNAHAS, AM ;
MASTERSTHOMAS, A ;
BRADY, SA ;
FARRINGTON, K ;
WILKINSON, V ;
HILSON, AJW ;
VARGHESE, Z ;
MOORHEAD, JF .
BRITISH MEDICAL JOURNAL, 1984, 289 (6455) :1337-1341